About Ceptaris Therapeutics
Ceptaris Therapeutics is a Healthcare company based in Malvern (United States) founded in 2002, and was acquired by Actelion in July 2013. Mechlorethamine gel for mycosis fungoides is developed by Ceptaris Therapeutics. Ceptaris Therapeutics has raised $49.04 million across 10 funding rounds from investors including SVB, Actelion and HHS. Its focus areas include Life Sciences, Oncology, Drugs and Diversified.
Company details
Ceptaris Therapeutics was founded in 2002 and headquartered in Malvern, United States, as a clinical-stage biopharmaceutical company. Focus was placed on developing Mechlorethamine gel, marketed as Valchlor, for treating early-stage (I-IIA) mycosis fungoides, a form of cutaneous T-cell lymphoma. Operations centered on oncology therapeutics until acquisition by Actelion in 2013, following FDA rejection of the drug application the prior year. The company was previously known as Yaupon.
- Headquarters Malvern, United States
- Stage Acquired
- SectorsHealthcare
- Phone•••• ••••
- Website ceptaris.com
- Social LinkedIn
- Acquired by Actelion (Jul 2013)
Funding Insights of Ceptaris Therapeutics
Ceptaris Therapeutics has successfully raised a total of $49.04M across 10 strategic funding rounds. The most recent funding activity was a Series D round of $10 million completed in May 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $49.04M
- Total Rounds 10
- Last Round Series D — $10M
- First Round $750,000
(Jun 2002)
- Investors Count 11
All 10 funding rounds of Ceptaris Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2012 | $10M | Series D | – | Palo Alto Investors, Burrill and Company | – |
| Feb 2012 | $15M | Debt – Conventional | – | – | |
| Aug 2011 | $14.4M | Series D | – | Burrill and Company, Aperture Venture Partners | |
| Nov 2010 | $2M | Series C | – | – | – |
| Aug 2009 | $3.14M | Series C | – | – | – |
| Mar 2008 | $215,604 | Grant | – | – | |
| Nov 2007 | $14.5M | Series C | – | – | |
| Nov 2006 | $4M | Series B | – | Osage Venture Partners | |
| Jun 2005 | $250,000 | Seed | – | – | |
| Jun 2002 | $750,000 | Seed | – | – | – |
12 investors in total: 12 institutional.
Investors in Ceptaris Therapeutics
Ceptaris Therapeutics has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include SVB, Actelion and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare sector investments are managed through private equity strategies. | pa-investors.com | Palo Alto, United States | ||
A healthcare-focused investment firm supporting innovative company growth. | aperturevp.com | |||
| bioadvance.com | ||||
Corporate-backed venture capital is focused on fintech and multiple sectors. | thirdpointventures.com | Menlo Park, United States | ||
Venture capital and private equity firm | vivocapital.com | Palo Alto, United States | ||
Early-stage venture capital fund investing in B2B software startups | osageventurepartners.com | Bala Cynwyd, United States | ||
Venture debt firm focused on the life sciences sector | 2002 | oxfordfinance.com | Alexandria, United States | |
Technology ecosystem growth is supported in Southeastern Pennsylvania. | sep.benfranklin.org | Philadelphia, United States | ||
Multi-category products are listed on an online B2B platform. | 1994 | burrillandco.com | Wuxi, China | |
Banking services are provided to innovative companies, investors, and individuals. | 1983 | svb.com | Santa Clara, United States |
Investor details for Ceptaris Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Ceptaris Therapeutics
4 dated milestones of Ceptaris Therapeutics across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Ceptaris Therapeutics is founded.
- Funding First funding round of $750K.
- Funding Latest funding round, Series D, of $10.0M.
- Exit Acquired by Actelion.
Top companies in Oncology
3 companies that operate in the same segment as Ceptaris Therapeutics (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ceptaris Therapeutics
Complete news archive for Ceptaris Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ceptaris Therapeutics
Ceptaris Therapeutics was founded in 2002.
Ceptaris Therapeutics is headquartered in Malvern, United States. It is registered at Malvern, Pennsylvania, United States.
Ceptaris Therapeutics is a funded company, having raised a total of $49.04M across 10 funding rounds to date. The company's 1st funding round was a Seed of $750K, raised on Jun 2002.
Ceptaris Therapeutics was founded in 2002 and headquartered in Malvern, United States, as a clinical-stage biopharmaceutical company. Focus was placed on developing Mechlorethamine gel, marketed as Valchlor, for treating early-stage (I-IIA) mycosis fungoides, a form of cutaneous T-cell lymphoma. Operations centered on oncology therapeutics until acquisition by Actelion in 2013, following FDA rejection of the drug application the prior year. The company was previously known as Yaupon.
Ceptaris Therapeutics has 12 investors. Key investors include SVB, Actelion, HHS, Oxford Finance, and Burrill and Company.
Yes. Ceptaris Therapeutics was acquired by Actelion in July 2013.